Biocogniv Analysis: $6M Raised
What is Biocogniv?
Biocogniv is an AI diagnostic company that focuses on time-critical medical conditions, especially sepsis. Its LinkedIn page describes the product as an AI diagnostic platform with the first FDA Breakthrough Designation in sepsis. The company was acquired by BETA Technologies, and its LinkedIn presence shows 657 followers.
Location
South Burlington, Vermont 05403, United States
Employees
1-10
Founded
2019
Revenue
$2.6M
Business Model
Revenue generated through software sales and licensing to healthcare institutions.
Product Features & Capabilities
- AI-based predictive diagnostics, Sepsis aiMarker™ detects and predicts sepsis up to 72 hours in advance using routine laboratory panels.
How much Biocogniv raised
Seed - $6 million
March 16, 2022Lead Investor: Breyer Capital
Who are the founders of Biocogniv
AA
Artur Adib
Founder
Market Focus
Biocogniv primarily focuses on the healthcare industry, specifically in the field of predictive diagnostics using artificial intelligence to assist in recognizing acute medical conditions.
Investors
- Unpopular Ventures
- Inflect Health
- Y Combinator
- America's Seed Fund
- 1984 Ventures
- AltaIR Capital
- Breyer Capital
- Dudley Fund
- Hula
Competitors Overview
Biocogniv operates in the AI-based predictive diagnostics market, focusing on helping healthcare providers recognize acute conditions early. Its main competitors include:
-
Digital Reasoning: Specializes in AI-based consumer behavior analysis, primarily for financial institutions. It has raised $153 million, which allows for significant investment in technology and development. This focus on finance differentiates it from Biocogniv's healthcare-centric approach.
-
Agamon: Offers an AI and cloud-based platform for clinical data analytics, with $8 million in funding. Agamon's emphasis on clinical data analytics positions it closely to Biocogniv, but it may not have the same focus on predictive diagnostics for acute conditions.
-
Pieces Tech: Provides a predictive analytics platform aimed at identifying and preventing adverse events in healthcare, having raised $88.2 million. Its focus on predictive analytics aligns with Biocogniv's mission, but it may have broader applications beyond acute condition recognition.
-
Bayesian Health: Specializes in clinical AI augmentation, providing an adaptive AI platform for healthcare data analysis. This focus on AI augmentation offers a different approach compared to Biocogniv's specific predictive diagnostics.
-
Epic: A major player in health IT, Epic develops software solutions for patient care. While not directly a competitor in predictive diagnostics, its comprehensive healthcare software solutions could overlap with Biocogniv's offerings.
-
Dascena: Previously focused on machine learning algorithms in healthcare but has ceased operations, which may impact its competitive standing.
Biocogniv's unique advantage lies in its specific focus on AI-powered diagnostics for acute conditions, particularly its flagship product AI-COVIDTM, which targets early detection of critical health issues.
See something that needs updating? Suggest edits to this profile.